TY - JOUR
T1 - Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits
AU - Xu, Zhiqiang
AU - Xiao, Na
AU - Chen, Yali
AU - Huang, Huang
AU - Marshall, Charles
AU - Gao, Junying
AU - Cai, Zhiyou
AU - Wu, Ting
AU - Hu, Gang
AU - Xiao, Ming
N1 - Publisher Copyright:
© 2015 Xu et al.
PY - 2015/11/2
Y1 - 2015/11/2
N2 - Background: Preventing or reducing amyloid-beta (Aβ) accumulation in the brain is an important therapeutic strategy for Alzheimer's disease (AD). Recent studies showed that the water channel aquaporin-4 (AQP4) mediates soluble Aβ clearance from the brain parenchyma along the paravascular pathway. However the direct evidence for roles of AQP4 in the pathophysiology of AD remains absent. Results: Here, we reported that the deletion of AQP4 exacerbated cognitive deficits of 12-moth old APP/PS1 mice, with increases in Aβ accumulation, cerebral amyloid angiopathy and loss of synaptic protein and brain-derived neurotrophic factor in the hippocampus and cortex. Furthermore, AQP4 deficiency increased atrophy of astrocytes with significant decreases in interleukin-1 beta and nonsignficant decreases in interleukin-6 and tumor necrosis factor-alpha in hippocampal and cerebral samples. Conclusions: These results suggest that AQP4 attenuates Aβ pathogenesis despite its potentially inflammatory side-effects, thus serving as a promising target for treating AD.
AB - Background: Preventing or reducing amyloid-beta (Aβ) accumulation in the brain is an important therapeutic strategy for Alzheimer's disease (AD). Recent studies showed that the water channel aquaporin-4 (AQP4) mediates soluble Aβ clearance from the brain parenchyma along the paravascular pathway. However the direct evidence for roles of AQP4 in the pathophysiology of AD remains absent. Results: Here, we reported that the deletion of AQP4 exacerbated cognitive deficits of 12-moth old APP/PS1 mice, with increases in Aβ accumulation, cerebral amyloid angiopathy and loss of synaptic protein and brain-derived neurotrophic factor in the hippocampus and cortex. Furthermore, AQP4 deficiency increased atrophy of astrocytes with significant decreases in interleukin-1 beta and nonsignficant decreases in interleukin-6 and tumor necrosis factor-alpha in hippocampal and cerebral samples. Conclusions: These results suggest that AQP4 attenuates Aβ pathogenesis despite its potentially inflammatory side-effects, thus serving as a promising target for treating AD.
KW - AQP4
KW - Alzheimer's disease
KW - Amyloid-beta
KW - Astrocytes
KW - Paravascular pathway
UR - http://www.scopus.com/inward/record.url?scp=84959115075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959115075&partnerID=8YFLogxK
U2 - 10.1186/s13024-015-0056-1
DO - 10.1186/s13024-015-0056-1
M3 - Article
C2 - 26526066
AN - SCOPUS:84959115075
SN - 1750-1326
VL - 10
JO - Molecular Neurodegeneration
JF - Molecular Neurodegeneration
IS - 1
M1 - 56
ER -